Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer’s Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal Controls

• Published in: Journal of proteome research Vol. 20; no. 9; pp. 4303 - 4317
• Main Authors: Jasbi, Paniz, Shi, Xiaojian, Chu, Ping, Elliott, Natalie, Hudson, Haley, Jones, Douglas, Serrano, Geidy, Chow, Brandon, Beach, Thomas G, Liu, Li, Jentarra, Garilyn, Gu, Haiwei
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 03.09.2021
• Subjects: Alzheimer Disease - diagnosis; Biomarkers; blood; cognitive disorders; Cognitive Dysfunction - diagnosis; data collection; death; dodecanoic acid; fatty acid metabolism; Female; females; Gas Chromatography-Mass Spectrometry; Humans; lysine; Male; males; mass spectrometry; metabolites; metabolome; Metabolomics; mitochondria; monitoring; multivariate analysis; myristic acid; Neocortex; palmitic acid; palmitoleic acid; proteome; stearic acid; therapeutics; pathogenesis; mass spectrometry; Alzheimer’s disease; metabolomics; biomarkers
• ISSN: 1535-3893; 1535-3907; 1535-3907
• DOI: 10.1021/acs.jproteome.1c00290

Alzheimer’s disease (AD) is the most common cause of dementia, accounting for an estimated 60–80% of cases, and is the sixth-leading cause of death in the United States. While considerable advancements have been made in the clinical care of AD, it remains a complicated disorder that can be difficult...